Portal blood flow in nonalcoholic fatty liver disease during the treatment

Authors

  • Александр Петрович Козлов Kharkiv National University named after V.N. Karazin Svobody sq., 6, Kharkov, Ukraine, 61077, Ukraine

DOI:

https://doi.org/10.15587/2313-8416.2014.30424

Keywords:

nonalcoholic fatty liver disease, hypertension, coronary heart disease, portal blood flow

Abstract

The state of portal hemodynamics in non-alcoholic fatty liver disease in combination with hypertension and coronary heart disease during the treatment is investigated. Complex therapy significantly decreased the ratio of portosystemic shunt, which is a sign of decrease in portal pressure and hindered the development of portopulmonary syndrome.

Author Biography

Александр Петрович Козлов, Kharkiv National University named after V.N. Karazin Svobody sq., 6, Kharkov, Ukraine, 61077

Assistant

Department of Hygiene and Social Medicine, Medical Faculty

References

Storozhakov, G. I., Ivkova, A. N. (2009). Patogeneticheskie aspektyi fibrogeneza pri hronicheskih zabolevaniyah pecheni (Pathogenetic aspects of fibrogenesis in chronic liver diseases). Clinical Perspectives in Gastroenterology, Hepatology, 2, 3–10.

Agafonov, A. V., Tuev, A. V., Nekrutenko, L. A., Bochkova, Yu. V. (2005). Arterialnoe remodelirovanie u bolnyih arterialnoy gipertenziey pozhilogo i starshego vozrasta (Arterial remodeling in hypertensive patients of elderly and older). Russian Cardiology Journal, 3, 25–28.

Versari, D., Daghini, E., Virdis, A. et al. (2009). Endothelium–dependent contractions and endothelial dysfunction in human hypertension. British Journal of Pharmacology, 157 (4), 527–536. doi: 10.1111/j.1476-5381.2009.00240.x

Oparil, S., Zaman, A., Calhoun, D. A. (2003). Pathogenesis of arterial hypertension. Annals of Internal Medicine, 139, 7617–7626.

Chen, J., Talwalkar, J. A., Yin, M., Glaser, K. J., Sanderson, S. O., Ehman, R. L. (2011). Early Detection of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease by Using MR Elastography. Radiology, 259 (3), 749–756. doi: 10.1148/radiol.11101942

V.W. Wong , W.C. Chu G. L.-H. Wong, R. S.-M. Chan, A. M.-L. Chim, A. Ong, D. K.-W. Yeung, K. K.-L. Yiu, S. H.-T. Chu, J. Woo, F. K.-L. Chan, H. L.-Y. Chan (2011). Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut, 61 (3), 409–415. doi: 10.1136/gutjnl-2011-300342

Thiruvagounder, M., Khan, S., Sheriff, D. S. (2010). The prevalence of metabolic syndrome in India. Biochemia Medica, 20 (2), 249–252.

Ioannou, G. N., Weiss, N. S., Boyko, E. J., Mozaffarian, D., Lee, S. P. (2006). Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology, 43 (5), 1145–1151. doi: 10.1002/hep.21171

Kozlov, O. P. (2012). Stan portalnogo krovotoku u hvorih na nealkogolnu zhirovu hvorobu pechInki (Status of portal blood flow in patients with nonalcoholic fatty liver disease). Actual problems of modern medicine: Bulletin of the Ukrainian Medical Dental Academy, 12/3 (39), 46–50.

Paschos, P., Tziomalos, K. (2012). Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment . World J. Hepatol., 4 (12), 327–331.

Yoshiji, H., Kuriyama, S., Fukui, H. (2007). Blockade of renin-angiotensin system in antifibrotic therapy. Journal of Gastroenterology and Hepatology, 22 (s1), 893–895. doi: 10.1111/j.1440-1746.2006.04663.x

Huang, M. L., Li, X., Meng, Y., Xiao, B., Ma, Q., Ying, S. S., Wu, P. S., Zhang, Z. S. (2010). Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. Clinical and Experimental Pharmacology and Physiology, 37 (1). – Р. 1–6. doi: 10.1111/j.1440-1681.2009.05302.x

Li, L., Luo, Z., Yu, H., Feng, X., Wang, P., Chen, J., Pu, Y., Zhao, Y., He, H., Zhong, J., Liu, D., Zhu, Z. (2013). Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation. Diabetes, 62 (3), 762–774. doi: 10.2337/db12-0570

Drake, J. I., Gomez-Arroyo, J., Dumur, C. I., Kraskauskas, D., Natarajan, R., Bogaard, H. J., Fawcett, P., Voelkel, N. F. (2013). Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiological Genomics, 45 (12), 449–461. doi: 10.1152/physiolgenomics.00166.2012

Hobolth, L., Bendtsen, F., Hansen, E. F. (2014). Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study. Digestive and Liver Disease, 46 (3), 251–256. doi: 10.1016/j.dld.2013.10.013

Ko, S. Y., Kim, J. H., Choe, W. H., Kwon, S. Y., Lee, C. H. (2012). Pharmacotherapy alone vs endoscopic variceal ligation combination for secondary prevention of oesophageal variceal bleeding: meta-analysis. Liver International, 32 (5), 867–869. doi: 10.1111/j.1478-3231.2011.02681.x

Vize-Hripunova, M. A., Zagoranskaya, N. S., Ismailova, S. A. (2005). Effektivnost lizinoprila v korrektsii portalnoy gipertenzii u bolnyih tsirrozom pecheni (Efficacy of lisinopril in the correction of portal hypertension in patients with liver cirrhosis). Russian Journal of Gastroenterology, Hepatology and Coloproctology, 26, 69.

Published

2014-12-22

Issue

Section

Medical